These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 24921678)

  • 21. [Depression and pain: prevalence and clinical implication].
    Pelissolo A
    Presse Med; 2009 Mar; 38(3):385-91. PubMed ID: 18977630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SNRIs: mechanism of action and clinical features.
    Lambert O; Bourin M
    Expert Rev Neurother; 2002 Nov; 2(6):849-58. PubMed ID: 19810918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New treatment of depression in Parkinson's disease.
    Maruyama T
    Int J Psychiatry Clin Pract; 2003; 7 Suppl 1():25-7. PubMed ID: 24937417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Painful physical symptoms in depression: a clinical challenge.
    Wise TN; Fishbain DA; Holder-Perkins V
    Pain Med; 2007 Sep; 8 Suppl 2():S75-82. PubMed ID: 17714118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antidepressants in the treatment of fibromyalgia.
    Moret C; Briley M
    Neuropsychiatr Dis Treat; 2006 Dec; 2(4):537-48. PubMed ID: 19412502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Posttraumatic stress disorder (PTSD) as a consequence of the interaction between an individual genetic susceptibility, a traumatogenic event and a social context].
    Auxéméry Y
    Encephale; 2012 Oct; 38(5):373-80. PubMed ID: 23062450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Milnacipran: serotonin-noradrenaline reuptake inhibitor approved for fibromyalgia may be a useful antidepressant.
    Keks NA; Hope J; Keogh S; Copolov DL
    Australas Psychiatry; 2018 Oct; 26(5):537-540. PubMed ID: 30198305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia.
    Vitton O; Gendreau M; Gendreau J; Kranzler J; Rao SG
    Hum Psychopharmacol; 2004 Oct; 19 Suppl 1():S27-35. PubMed ID: 15378666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unexplained Painful Physical Symptoms in Patients with Major Depressive Disorder: Prevalence, Pathophysiology and Management.
    Jaracz J; Gattner K; Jaracz K; Górna K
    CNS Drugs; 2016 Apr; 30(4):293-304. PubMed ID: 27048351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antidepressant therapy for unexplained symptoms and symptom syndromes.
    O'Malley PG; Jackson JL; Santoro J; Tomkins G; Balden E; Kroenke K
    J Fam Pract; 1999 Dec; 48(12):980-90. PubMed ID: 10628579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strategies to Treat Chronic Pain and Strengthen Impaired Descending Noradrenergic Inhibitory System.
    Hayashida KI; Obata H
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30769838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Off-label Antidepressant Use for Treatment and Management of Chronic Pain: Evolving Understanding and Comprehensive Review.
    Urits I; Peck J; Orhurhu MS; Wolf J; Patel R; Orhurhu V; Kaye AD; Viswanath O
    Curr Pain Headache Rep; 2019 Jul; 23(9):66. PubMed ID: 31359175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Look at Commonly Utilized Serotonin Noradrenaline Reuptake Inhibitors (SNRIs) in Chronic Pain.
    Robinson C; Dalal S; Chitneni A; Patil A; Berger AA; Mahmood S; Orhurhu V; Kaye AD; Hasoon J
    Health Psychol Res; 2022; 10(3):32309. PubMed ID: 35774919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physiology to functionality: the brain and neurotransmitter activity.
    Racagni G; Brunello N
    Int Clin Psychopharmacol; 1999 May; 14 Suppl 1():S3-7. PubMed ID: 10468322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A case report of Milnacipran in phantom-limb pain.
    Chalana H
    Asian J Psychiatr; 2010 Sep; 3(3):155-6. PubMed ID: 23051576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rescue of Noradrenergic System as a Novel Pharmacological Strategy in the Treatment of Chronic Pain: Focus on Microglia Activation.
    Caraci F; Merlo S; Drago F; Caruso G; Parenti C; Sortino MA
    Front Pharmacol; 2019; 10():1024. PubMed ID: 31572196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibromyalgia: diagnosis and management for the primary healthcare provider.
    Huynh CN; Yanni LM; Morgan LA
    J Womens Health (Larchmt); 2008 Oct; 17(8):1379-87. PubMed ID: 18788986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancing central noradrenergic function in depression: is there still a place for a new antidepressant?
    Pinder RM
    Neuropsychiatr Dis Treat; 2005 Mar; 1(1):3-7. PubMed ID: 18568121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors.
    Briley M; Moret C
    Neuropsychiatr Dis Treat; 2010 Oct; 6():647-55. PubMed ID: 20957125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improvement of the noradrenergic symptom cluster following treatment with milnacipran.
    Kasper S; Meshkat D; Kutzelnigg A
    Neuropsychiatr Dis Treat; 2011; 7(Suppl 1):21-7. PubMed ID: 21750625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.